| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
51,620,000 |
| Market
Cap: |
10.32(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.1993 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Humanigen is a biopharmaceutical company focused on developing its immuno-oncology and immunology portfolio of monoclonal antibodies. Co. is focusing on the development of its key product candidate, lenzilumab, its Humaneered® anti-human GM-CSF immunotherapy, through a clinical research agreement to study the effect of lenzilumab on the safety of Yescarta®, axicabtagene ciloleucel including cytokine release syndrome, and neurotoxicity. Co. is creates combinatory gene-edited CAR-T therapies to improve efficacy. Co. is also developing its own chimeric antigen receptor T-cell programs based on the backbone of ifabotuzumab and HGEN005, in unmet medical need and rare/orphan oncology conditions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,042,996 |
| Total Buy Value |
$0 |
$0 |
$0 |
$2,263,990 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
386,350 |
386,350 |
| Total Sell Value |
$0 |
$0 |
$4,250 |
$4,250 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2023-10-18 |
4 |
S |
$0.01 |
$4,250 |
I/I |
(386,350) |
8,398,871 |
|
99% |
|
| Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2022-05-20 |
4 |
B |
$2.23 |
$1,215,347 |
I/I |
545,488 |
8,675,081 |
0.01 |
-92% |
|
| Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2022-05-19 |
4 |
B |
$2.19 |
$707,844 |
I/I |
323,808 |
8,293,240 |
0.01 |
-93% |
|
| Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2022-05-18 |
4 |
B |
$1.96 |
$340,799 |
I/I |
173,700 |
8,066,575 |
0.01 |
-91% |
|
| Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2022-03-11 |
4 |
B |
$3.00 |
$3,000,000 |
I/I |
1,000,000 |
7,944,985 |
0.01 |
-84% |
|
| Kilcoyne Adrian |
Chief Medical Officer |
• – – |
2022-03-09 |
4 |
B |
$2.78 |
$13,900 |
D/D |
5,000 |
12,000 |
0.01 |
-84% |
|
| Kilcoyne Adrian |
Chief Medical Officer |
• – – |
2022-03-08 |
4 |
B |
$2.53 |
$17,710 |
D/D |
7,000 |
7,000 |
0.01 |
-83% |
|
| Durrant Cameron |
Chief Executive Officer |
• • – |
2022-03-02 |
4 |
B |
$2.34 |
$93,600 |
I/I |
40,000 |
70,000 |
0.01 |
23% |
|
| Edward P. Jordan |
Chief Commercial Officer |
• – – |
2022-03-02 |
4 |
B |
$2.32 |
$29,000 |
D/D |
12,500 |
12,500 |
0.01 |
23% |
|
| Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2021-08-12 |
4 |
AS |
$17.16 |
$987,564 |
I/I |
(57,551) |
7,266,296 |
|
-78% |
|
| Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2021-08-11 |
4 |
AS |
$17.07 |
$1,872,146 |
I/I |
(109,647) |
7,308,021 |
|
-78% |
|
| Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2021-07-29 |
4 |
AS |
$17.03 |
$500,703 |
I/I |
(29,394) |
7,366,204 |
|
-65% |
|
| Cheval Holdings, Ltd. |
Chief Scientific Officer |
• • • |
2021-07-28 |
4 |
AS |
$17.04 |
$165,162 |
I/I |
(9,692) |
7,387,515 |
|
-68% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-07-23 |
4 |
AS |
$17.04 |
$95,155 |
I/I |
(5,584) |
7,394,542 |
|
-63% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-07-22 |
4 |
AS |
$17.04 |
$3,032,796 |
I/I |
(178,005) |
7,398,590 |
|
-66% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-07-21 |
4 |
AS |
$17.14 |
$2,275,124 |
I/I |
(132,764) |
7,527,644 |
|
-64% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-07-14 |
4 |
AS |
$17.06 |
$258,847 |
I/I |
(15,177) |
7,623,898 |
|
-64% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-07-09 |
4 |
AS |
$17.37 |
$5,142,767 |
I/I |
(296,036) |
7,634,901 |
|
-61% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-07-08 |
4 |
AS |
$17.17 |
$824,111 |
I/I |
(48,010) |
7,849,527 |
|
-62% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-07-02 |
4 |
AS |
$17.12 |
$1,760,758 |
I/I |
(102,848) |
7,884,334 |
|
-62% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-07-01 |
4 |
AS |
$17.10 |
$2,410,667 |
I/I |
(140,992) |
7,958,899 |
|
-61% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-06-30 |
4 |
AS |
$17.28 |
$3,787,954 |
I/I |
(219,256) |
8,061,118 |
|
-57% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-06-25 |
4 |
AS |
$17.80 |
$17,803,500 |
I/I |
(1,000,000) |
8,220,079 |
|
-56% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-06-24 |
4 |
AS |
$18.37 |
$2,563,831 |
I/I |
(139,529) |
8,945,079 |
|
-59% |
|
| Black Horse Capital Master Fund Ltd. |
Chief Scientific Officer |
• • • |
2021-06-23 |
4 |
AS |
$18.28 |
$2,434,182 |
I/I |
(133,126) |
9,046,237 |
|
-60% |
|
160 Records found
|
|
Page 1 of 7 |
|
|
0.01 (97.01%) 
